Dr. McDermott on Novel Immunotherapy Combinations in RCC – OncLive
OncLive |
Dr. McDermott on Novel Immunotherapy Combinations in RCC
OncLive David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses novel immunotherapy combinations for patients with metastatic renal cell carcinoma (RCC). According to McDermott, an exciting area of … |
